Recommended

FDA tightens COVID vaccine use
Decentralised manufacturing consortium launched
Trial boost for myasthenia gravis drug
FDA starts publishing daily AE data
WEBINAR | The Future of Sterility Testing: One-Day Results with Advanced RT-rt PCR Technology | 5 NOV
WEBINAR | Mastering Impurity Profiling: USP’s Evolving Standards and Strategies | 15 OCT
news

Janssen rebrands its identity

2
SHARES

Johnson & Johnson has updated the branding for its Janssen division, enabling its pharmaceutical and medtech segments to modernise and be more connected to its J&J brand.

Janssen rebrands its identity - Johnson & Johnson

Credit: Michael Vi / Shutterstock.com

The Janssen Pharmaceutical Companies of Johnson & Johnson has changed its name to Johnson & Johnson Innovative Medicine (J&J Innovative Medicine).

 

ACCESS your FREE COPY

 


This report addresses the key factors shaping pharmaceutical formulation, including regulation, QC and analysis.

Access the full report now to discover the techniques, tools and innovations that are transforming pharmaceutical formulation, and learn how to position your organisation for long-term success.

What you’ll discover:

  • Key trends shaping the pharmaceutical formulation sector
  • Innovations leading progress in pharmaceutical formulation and how senior professionals can harness their benefits
  • Considerations and best practices when utilising QbD during formulation of oral solid dosage forms
  • And more!

Don’t miss your chance to access this exclusive report ! Access now – it’s free

Johnson & Johnson is bringing together its divisions under the J&J brand name. While Janssen, J&J’s pharmaceutical division will be known as J&J Innovative Medicine, the company’s medical technology segment will continue to be named Johnson & Johnson MedTech.

A modern identity for Janssen

The new logo, colors, and font for J&J Innovative Medicine will be rolled out steadily across all company materials, product packaging, and branding assets over time.

This new re-brand for the company follows the appointment its new Executive Vice President, Pharmaceuticals, R&D, an ex- Sanofi executive, in February 2023.

Recent clinical trial news for Janssen’s RYBREVANT

J&J Innovative Medicine covers the following therapeutic areas: cardiovascular, metabolism & retina, immunology, infectious diseases, neuroscience, oncology, as well as pulmonary hypertension.

Earlier this week on 11 September, while still known as Janssen Pharmaceutical Companies of Johnson & Johnson, the firm announced that RYBREVANT® (amivantamab-vmjw) and Lazertinib plus chemotherapy provided a median progression-free survival (PFS) rate of 14 months in previously treated EGFR-mutated advanced non-small cell lung cancer (NSCLC).

The combination of RYBREVANT and lazertinib with chemotherapy demonstrated an objective response rate of 50 percent, according to data presented at International Association for the Study of Lung Cancer (IASLC) 2023 World Congress on Lung Cancer (WCLC).

Follow-up results from the Phase Ib/II CHRYSALIS-2 study cohort evaluated the safety and tolerability of the combination of RYBREVANT, a bispecific antibody targeting epidermal growth factor receptor (EGFR) and mesenchymal-epithelial transition (MET), with lazertinib, an oral third-generation EGFR tyrosine kinase inhibitor (TKI), plus platinum-based chemotherapy (carboplatin and pemetrexed) in relapsed/refractory (NSCLC) and EGFR mutations.

Branding innovation in the pharmaceutical industry

This week, Novartis has also finalised changes to its divisions. On 15 Sept 2023, shareholders of the company approved the proposed 100 percent Spin-off of Sandoz. The spin-off is projected to occur on or around October 4, 2023.

Transforming oncology with antibody therapeutics

Share via
Share via